Navigation Links
Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
Date:7/6/2008

with the control arm (30 percent versus 5 percent, (p <0.001)), and grade 3 neuropathy occurred in 4 percent of the OPAXIO patients, with no occurrences of grade 4 neuropathy. There was a lower incidence of alopecia in the OPAXIO arm (2 percent versus 5 percent respectively, p = 0.085), as well as fatigue (16 percent versus 25 percent, p= 0.055), asthenia (11 percent versus 16 percent, p = 0.169), and weight loss (7 percent versus 12 percent, p = 0.121).

Details of the Study

The phase III trial, reported by Mary E. R. O'Brien, M.D., F.R.C.P., et al, of the Royal Marsden Hospital and the Kent Cancer Centre in Surrey, UK, was a randomized, multi-center trial. The trial was conducted at 83 centers in ten countries, and randomized on a 1:1 ratio to evaluate the efficacy and safety of this regimen in patients with chemotherapy-nave NSCLC. Patients with advanced stage IIIb/IV NSCLC and PS 2 were treated with OPAXIO on day 1 of a 21-day cycle, while patients receiving gemcitabine were treated on days 1, 8, and 15 of each 28-day cycle. Vinorelbine was administered on days 1, 8, and 15 of each 21-day cycle. Patients received up to six cycles of treatment, and were not treated until significant toxicities were under control (less than or equal to grade 1). The primary objective was effect on survival, and secondary objectives were determining the efficacy and safety of the treatments.

About OPAXIO(TM)

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was previously branded as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, paclitaxel is rendered inactive, potentially sparing normal tissue's exposure to high levels of the active drug and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules l
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
2. Genzyme and Isis Complete Licensing of Mipomersen
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
10. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
11. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... NewCardio, Inc. (OTC Bulletin Board: NWCI ... Dr. Samuel George, NewCardio,s Senior Medical Advisor, will present ... dataset, conducted independently by the Cardiac Safety Research Consortium ... on December 9, 2010, at the headquarters of the ...
... The addition of Cimzia® (certolizumab pegol; CZP) to ... response, improved function and reduced disease activity in ... patients reflecting those seen in daily clinical practice ... clinical trial data were presented during the American ...
Cached Medicine Technology:NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 2NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 3NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 4New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 2New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 3New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 4New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 5New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 6New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 7New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 8New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 9New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 10
(Date:4/24/2014)... to receive at least if you,re an adolescent and ... found that 15- and 16-year-olds who find pleasure in pro-social ... less likely to become depressed than those who get a ... themselves. , The researchers detail their findings in the ... study focused on the ventral striatum, a brain region that ...
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
(Date:4/23/2014)... director at the National Institute of Arthritis and Musculoskeletal ... recipient of the Ross Prize in Molecular Medicine, conferred ... Medicine . The award will be given on June ... Manhattan, followed by scientific presentations by Dr. O,Shea and ... Institutes of Health. , The award, which includes a ...
(Date:4/23/2014)... have developed a way to detect and measure cancer ... particles with tails of synthetic DNA., A team led ... used gold nanoparticles to target and bind to fragments ... variants, which can indicate the presence and stage of ... in a cell can be determined by examining the ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... is too expensive to eat a well-balanced diet may be surprised ... have changed eating healthily may actually be cheaper than their current ... New York, suggested that a healthy diet does not have to ... time, the cost of a healthy diet may be less than ...
... of removing cancerous kidneys through a small incision with ... and instuments. This is the hand-assisted Laproscopic technique, which ... standard laproscopic procedure. ,The research, being presented at the ... from the University of Michigan(U-M) Health System,// U.S., may ...
... which can be hard on the body. Stress affects the ... take to reduce impact of stress, and it's probably good ... sales rep, found that appointments and deadlines can be stressful. ... seem small, but they do tend to affect your blood ...
... Epidemiology, Biomarkers and Prevention, eating a daily multivitamin with ... the genetic risk of developing colon cancer. ,According ... colon cancer -- a parent or sibling are at ... Fuchs, lead investigator and assistant professor of medicine at ...
... by a biomedical engineer at the University of Pittsburgh ... of your eyes. The prototype device merges the visual ... ultrasound scan of what lies beneath. It creates the ... actual 3D location with the patient, showing blood vessels, ...
... nanobots it not with us yet, a tiny, inexpensive motor ... in the near future, according to Penn State engineer.,The smallest ... State’s Materials Research Institute is about the size of a ... 4 mm long.// ,Tiny, but powerfull, the smallest motor’s ...
Cached Medicine News:Health News:Eating healthy is cost effective 2Health News:Lessening operation and recovery time 2Health News:Folic Acid blows Gene-based Colon Cancer 2Health News:New form of ultrasonic vision 2Health News:Mini motor for micromedical applications 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: